Abstract 1570
Background
Systemic chemotherapy (SC) has a negative effect on ovarian functions. The aim of this study is to investigate the effect of SC on anti-müllerian hormone (AMH) levels, antral follicle counts (AFC) and ovarian volumes (MOV) in patients with BC.
Methods
The demographic, clinical and pathological features of premenopausal breast cancer (BC) patients who were operated in the Istanbul Florence Nightingale Hospital were recorded. AMH levels, AFC and MOV measurements were performed before and after adjuvant SC in 3-month periods. The patients who did not have menstruel cycles for 6 months or longer had been classified as chemotherapy induced amenorrhea (CIA). The effects of different chemotherapy regimens on AMH, AFC and MOV in terms menstruel cycles resumption and CIA were investigated.
Results
Seventy one patients were eligible for the study, and median age of them was 38 years (ranged from 23 to 51 years). Median follow-up was 37 months (ranged from 20 to 51 months), CIA developed in 62% of patients. AMH, AFC, and MOV significantly decreased one year after SC (p < 0.0001). AMH before chemotherapy (median: 1,520 vs 0,755, p = 0.001), at the end of first year (median: 0,073 vs 0,010 ng/ml, p = 0.030) and pre-treatment AFC (median12 vs 4,50, p = 0.026) was lower in patients with CIA comparing those without CIA. In multivariate logistic regression analysis, AMH levels (OR:0.273, 95%: 0.102 – 0.733, p = 0.010) and AFC (OR: 1,180, 95% CI; 1,016-1,369, p = 0.030) before SC were the most valuable and earliest factors to predict CIA. There were no significant relationships between age of the patients (≤30vs>30 ), BMI (30vs> 30), SC regimen and number of cycles (4 vs > 4) and CIA (p > 0.05).Table:
254P muitivariet analyses with logistic regrettion for CIA
UNIVARIET | MULTIVARIET | ||||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | OR | 95% CI | ||||||
ER | 0,19 | 0,038 | - | 0,891 | 0,035 | 0,002 | 0,000 | - 0,111 | 0,002 |
HER 2 | 0.80 | 0,435 | - | 2,936 | 1,130 | ||||
ALND PERFORMED | 1,75 | 0,653 | - | 4,702 | 0,265 | ||||
AMH-1 | 0,64 | 0,454 | - | 0,914 | 0,014 | 0,273 | 0,102 | - 0,733 | 0,010 |
AMH-5 | 0,23 | 0,063 | - | 0,812 | 0,023 | 0,009 | 0,000 | - 0,754 | 0,037 |
AFC-1 | 0,87 | 0,780 | - | 0,961 | 0,007 | 0,735 | 0,572 | - 0,944 | 0,016 |
AFC-5 | 0,93 | 0,741 | - | 1,165 | 0,527 | ||||
MOV-1 | 1,00 | 0,987 | - | 1,021 | 0,686 | ||||
MOV-5 | 0,98 | 0,854 | - | 1,158 | 0,790 | ||||
TAXANE/W&İTHOUTTAXANE | 0,71 | 0,267 | - | 1,910 | 0,503 | ||||
TC/AC | 0,85 | 0,209 | - | 3,491 | 0,825 | ||||
AGE 35 | 4,66 | 1,613 | - | 13,498 | 0,004 | ||||
CHEMONUMBER | 0,24 | 0,080 | - | 0,766 | 0,017 | ||||
BMI 25 | 2,57 | 0,929 | - | 7,118 | 0,069 |
Conclusions
SC significantly decreases AMH and AFC values independently of chemotherapeutic agents in patients with BC. The low AMH levels and less AFC before SC may predict CIA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
İstanbul Demiroğlu Bilim University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3425 - Feasibility and impact of prospective DPYD screening in the Irish population
Presenter: Mohammed Zameer
Session: Poster Display session 2
Resources:
Abstract
1972 - Diet-derived metabolites and the risk of colorectal cancer: a nested case-control study in a population-based cohort, the Singapore Chinese Health Study
Presenter: Dawn Chong
Session: Poster Display session 2
Resources:
Abstract
4103 - Loss of subcutaneous adipose tissue during chemotherapy predicts reduced survival in patients with incurable colorectal cancer undergoing palliative therapy
Presenter: Erin Stella Sullivan
Session: Poster Display session 2
Resources:
Abstract
4309 - Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab.
Presenter: Bozena Cybulska-Stopa
Session: Poster Display session 2
Resources:
Abstract
3554 - Patient characteristics associated with poor performance status, ECOG 2-3, and effect on survival in 1086 Finnish metastatic colorectal cancers (mCRC) nationwide (prospective RAXO study)
Presenter: Pia Österlund
Session: Poster Display session 2
Resources:
Abstract
4572 - Discovery and Diagnosis of Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results from a European Survey
Presenter: Iga Rawicka
Session: Poster Display session 2
Resources:
Abstract
4783 - Adherence to recommended intake of calcium and colorectal cancer risk in the HEXA study
Presenter: Jeeyoo Lee
Session: Poster Display session 2
Resources:
Abstract
5106 - Body size, sex and sidedness of incident colorectal cancer in a prospective Swedish cohort study
Presenter: Christina Siesing
Session: Poster Display session 2
Resources:
Abstract
3364 - Middle East & North Africa Registry to characterize RAS mutation status and tumor specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)
Presenter: Mohamed Oukkal
Session: Poster Display session 2
Resources:
Abstract
3668 - Patient Demographics and Management Landscape of Metastatic Colorectal Cancer in the Third Line Setting: real-world data in an Australian Population
Presenter: Sandy Tun Min
Session: Poster Display session 2
Resources:
Abstract